North America Monoclonal Antibodies Market Forecast 2028 By Application (Oncology, Autoimmune Diseases, Infectious Diseases), By Type (Fully Human, Humanized, Chimeric), By End-use (Hospitals, Specialty Centers), Research Report, Country Outlook (U.S., Canada), COVID-19 Impact Statistics, Price Trends, Historic Data, Growth Prospects, Competitive Industry Share
Published Date: April 2022   |   Report ID: GR1896   |   Delivery: PDF  Request Free Sample

Report Content

Chapter 1   Methodology

1.1    Definition and forecast parameters

1.1.1    Definitions

1.1.2    Methodology and forecast parameters

1.2    Data sources

1.3    References & sources

1.3.1    Secondary

1.3.2    Primary

Chapter 2   Executive Summary

2.1    North America monoclonal antibodies industry summary, 2017 – 2028

2.1.1    Country trends

2.1.2    Type trends

2.1.3    Application trends

2.1.4    End-use trends

Chapter 3   Industry Insights

3.1    Industry segmentation

3.2    Industry outlook, 2017 – 2028

3.3    Major factor analysis

3.3.1    Drivers

3.3.1.1   High rate of adoption and approval in the region

3.3.1.2   Rising applications of monoclonal antibodies including COVID-19

3.3.1.3   Funding for R&D of monoclonal antibodies in the U.S.

3.3.1.4   Increasing penetration of companies with mAb therapies in Canada

3.3.2    Industry pitfalls & challenges

3.3.2.1   High pricing of some monoclonal antibodies

3.3.2.2   Lack of sufficient insurance policies in the U.S.

3.4    Analysis of COVID-19 impact on the industry

3.5    Porter’s analysis

3.6    Competitive review, 2021

3.7    PEST analysis

Chapter 4   North America Monoclonal Antibodies Market, By Type

4.1    Market trends

4.2    Fully human

4.2.1    Market estimates and forecast, by country, 2017 – 2028 (USD Million)

4.3    Humanized

4.3.1    Market estimates and forecast, by country, 2017 – 2028 (USD Million)

4.4    Chimeric

4.4.1    Market estimates and forecast, by country, 2017 – 2028 (USD Million)

4.5    Others

4.5.1    Market estimates and forecast, by country, 2017 – 2028 (USD Million)

Chapter 5   North America Monoclonal Antibodies Market, By Application

5.1    Market trends

5.2    Oncology

5.2.1    Market estimates and forecast, by country, 2017 – 2028 (USD Million)

5.3    Autoimmune diseases

5.3.1    Market estimates and forecast, by country, 2017 – 2028 (USD Million)

5.4    Infectious diseases

5.4.1    Market estimates and forecast, by country, 2017 – 2028 (USD Million)

5.5    Others

5.5.1    Market estimates and forecast, by country, 2017 – 2028 (USD Million)

Chapter 6   North America Monoclonal Antibodies Market, By End-use

6.1    Market trends

6.2    Hospitals

6.2.1    Market estimates and forecast, by country, 2017 – 2028 (USD Million)

6.3    Specialty centers

6.3.1    Market estimates and forecast, by country, 2017 – 2028 (USD Million)

6.4    Others

6.4.1    Market estimates and forecast, by country, 2017 – 2028 (USD Million)

Chapter 7   North America Monoclonal Antibodies Market, By Country

7.1    Market trends

7.2    U.S.

7.2.1    Market estimates and forecast, by type, 2017 – 2028 (USD Million)

7.2.2    Market estimates and forecast, by application, 2017 – 2028 (USD Million)

7.2.3    Market estimates and forecast, by end-use, 2017 – 2028 (USD Million)

7.3    Canada

7.3.1    Market estimates and forecast, by type, 2017 – 2028 (USD Million)

7.3.2    Market estimates and forecast, by application, 2017 – 2028 (USD Million)

7.3.3    Market estimates and forecast, by end-use, 2017 – 2028 (USD Million)

Chapter 8   Company Profiles

8.1    F. Hoffmann-La Roche Ltd.

8.1.1    Business overview

8.1.2    Financial data

8.1.3    Product landscape

8.1.4    Strategic outlook

8.2    AbbVie Inc.

8.2.1    Business overview

8.2.2    Financial data

8.2.3    Product landscape

8.2.4    Strategic outlook

8.3    Amgen

8.3.1    Business overview

8.3.2    Financial data

8.3.3    Product landscape

8.3.4    Strategic outlook

8.4    Bristol Myers Squibb

8.4.1    Business overview

8.4.2    Financial data

8.4.3    Product landscape

8.4.4    Strategic outlook

8.5    Johnson & Johnson

8.5.1    Business overview

8.5.2    Financial data

8.5.3    Product landscape

8.5.4    Strategic outlook

8.6    Merck & Co., Inc.

8.6.1    Business overview

8.6.2    Financial data

8.6.3    Product landscape

8.6.4    Strategic outlook

8.7    Novartis AG

8.7.1    Business overview

8.7.2    Financial data

8.7.3    Product landscape

8.7.4    Strategic outlook

8.8    AstraZeneca

8.8.1    Business overview

8.8.2    Financial data

8.8.3    Product landscape

8.8.4    Strategic outlook

8.9    Eli Lilly and Company

8.9.1    Business overview

8.9.2    Financial data

8.9.3    Product landscape

8.9.4    Strategic outlook

8.10    GlaxoSmithKline plc

8.10.1    Business overview

8.10.2    Financial data

8.10.3    Product landscape

8.10.4    Strategic outlook